Navigation Links
Treatment With VP20621 (Non-Toxigenic Clostridium difficile; NTCD) In A Phase 2 Study Resulted In High Rates Of Colonization And Statistically Significant Reductions In Recurrence Of C. difficile Infection
Date:4/22/2013

Dale N. Gerding , Professor of Medicine at Loyola University Chicago.

About Clostridium difficile
One of the most serious problems facing the U.S. healthcare system today is hospital-acquired infections (HAIs) and Clostridium difficile infection is one of the most common and devastating HAIs.  The incidence of C. difficile observed in U.S. healthcare facilities more than doubled approximately every five years since 1999 and the reported mortality rates from C. difficile in the U.S. have more than quadrupled in the last decade to 14,000 per year. Elderly patients exposed to antibiotics, long-term care patients, or those who have a serious underlying illness are at greatest risk to contract the disease. Typical symptoms include diarrhea (which can be severe), fever, nausea, abdominal pain, and dehydration that can lead to life-threatening complications such as shock, megacolon, peritonitis and perforation of the colon.

About ViroPharma Incorporated
ViroPharma Incorporated is an international biopharmaceutical company committed to developing and commercializing novel solutions for physician specialists to address unmet medical needs of patients living with diseases that have few if any clinical therapeutic options. ViroPharma is developing a portfolio of therapeutics for rare and Orphan diseases including C1 esterase inhibitor deficiency, Friedreich's Ataxia, and adrenal insufficiency; and recurrent C. difficile infection (CDI). Our goal is to provide rewarding careers to employees, to create new standards of care in the way serious diseases are treated, and to build international partnerships with the patients, advocates, and health care professionals we serve. ViroPharma's commercial products address diseases including hereditary angioedema (HAE), seizures and C. difficile-associated diarrhea (CDAD); for full U.S. prescribing information on our products, please download the p
'/>"/>

SOURCE ViroPharma Incorporated
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Study Finds Utilizing Integrated Medical and Pharmacy Data Improves Ability to Forecast Use of High-cost Specialty Treatments
2. Aethlon Medical Note: An Unprecedented Data Point, The Single-Treatment Capture of Hepatitis C Virus (HCV) by the Aethlon Hemopurifier®
3. Onyx Pharmaceuticals Announces FDA Advisory Committee to Review Carfilzomib for the Treatment of Patients with Relapsed and Refractory Multiple Myeloma
4. Accuray Launches First Study to Compare CyberKnife® SBRT to Surgery and IMRT for Treatment of Early-Stage Prostate Cancer
5. Elekta, pioneer in treatment of cancer in brain disorders, to Move North America Headquarters to Atlanta
6. Ampio Awarded US and Canadian Patents that will Bolster the Commercialization of Optina™ for the treatment of Diabetic Macular Edema (DME)
7. National Patient Advocate Foundation Praises Signing of the Delaware Cancer Treatment Access Act into Law
8. Zogenix Submits New Drug Application (NDA) to U.S. Food and Drug Administration (FDA) for Zohydro™ for Treatment of Chronic Pain
9. Janssen Research & Development Submits XARELTO® (rivaroxaban) to U.S. FDA for the Treatment and Prevention of Recurrent Venous Thromboembolism
10. Study Results Demonstrate Analytical Treatment Interruption to Assess Antiviral Activity of Argoss Arcelis™ Personalized Immunotherapy for Treatment of HIV Patients, AGS-004, Is Acceptable Strategy for At Least 16 Weeks
11. Alder BioPharmaceuticals Inc. Initiates Phase 1 Clinical Study of Antibody Therapeutic Candidate for Treatment of Migraine, ALD403
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... , Jan. 15, 2014  A novel wearable injector slightly larger ... painless for patients to self-inject prescription drugs in the large ... cancer, blood diseases, autoimmune deficiencies, and genetic disorders.  ... to $220B by 2018, according to analysts.   Many of these ...
(Date:1/14/2014)... 2014 Dynamic Healthcare Services, Inc. ("DHS"), a portfolio company ... Progressive Home Medical Equipment, Inc. ("Progressive") of Clarion, ... the acquisition were not disclosed. Progressive is ... wide range of sleep, mobility, and respiratory products to customers ...
(Date:1/14/2014)...   Oligomerix, Inc. , a privately held company pioneering ... (AD) and related neurodegenerative disorders, announced today the relocation ... as of January 15, 2014 and expanded ... Medical College. Oligomerix, which is focused on ...
Breaking Medicine Technology:Enable Injections Presents A New Class of Injectors for Drug Delivery at PEPTalk, Drug Delivery Partnership Meetings 2Dynamic Healthcare Services Completes Progressive Home Medical Equipment of Clarion, PA Investment 2Dynamic Healthcare Services Completes Progressive Home Medical Equipment of Clarion, PA Investment 3Oligomerix Relocates Corporate Headquarters and Secures Additional Laboratory Space from New York Medical College 2
... Inc. (OTCBB: ECTE), a company developing its needle-free ... continuous glucose monitoring system and its Prelude™ SkinPrep ... Patrick T. Mooney, M.D., CEO, President and Chairman ... at the Jefferies 2011 Global Healthcare Conference. ...
... CHENGDU, China, June 3, 2011 /PRNewswire-Asia-FirstCall/ -- Tianyin Pharmaceutical ... pharmaceutical company that specializes in patented biopharmaceutical medicine, modernized ... announced that the Board of Directors has reinstated the ... to 3 million TPI,s common stock on the open ...
Cached Medicine Technology:TPI Board Reinstates Stock Repurchase Program 2
(Date:4/17/2014)... cause of neuronal death in Parkinson,s disease is still ... be mistaken for foreign invaders and killed by the ... diseases like type I diabetes, celiac disease, and multiple ... April 16, 2014, in Nature Communications . , ... Parkinson,s disease; but if true, it could lead to ...
(Date:4/17/2014)... team led by researchers at UC Davis has shown ... key role in cell division, also boosts the mitochondrial ... time the complex has been shown to perform both ... excellent target to control cellular energy production, potentially advancing ... online today in the journal Developmental Cell . ...
(Date:4/17/2014)... April 17, 2014 Meaningful long-term survival ... cancer of the abdomen when treated with cytoreductive ... to a first-of-its-size analysis by physicians at Wake ... has the largest reported, single-center experience with cytoreductive ... Levine, M.D., and analysis of 20 years, worth ...
(Date:4/17/2014)... 2014 Giving patients adrenaline after they suffer a cardiac ... prospects of surviving long-term, according to new research conducted ... patients who have a cardiac arrest get adrenaline, which ... for decades," said Dr. Steve Lin, an emergency physician ... advances in medical treatment, long-term survival rates of patients ...
(Date:4/16/2014)... The Translational Genomics Research Institute (TGen) recently honored two ... their support of TGen,s research into brain, colon and ... Scottsdale. , Catherine Ivy, Founder and President of The ... McCain Leadership Award, named for U.S. Sen. John McCain ...
Breaking Medicine News(10 mins):Health News:Is Parkinson's an autoimmune disease? 2Health News:Dual role: Key cell division proteins also power up mitochondria 2Health News:20 years of data shows treatment technique improvement for advanced abdominal cancer 2Health News:Adrenaline does little to increase patient's survival after cardiac arrest 2Health News:TGen honors Catherine Ivy and Craig Jackson with Leadership; Collaborative Spirit awards 2
... Drug Information Association (DIA), in collaboration with FDA, the Medical ... Radiopharmaceuticals (CORAR), PhRMA, and the American Medical Informatics Association (AMIA), ... Uses of Medical Imaging in the Development of New Biopharmaceutical ... ...
... is a break-through Nitinol wire product which features an exclusive ... acid solutions which cause embrittlement. The resulting NitiBrite™ ... other known methods. , ... West ...
... Komen for the Cure(R), the,leader of the global ... G. Komen for the Cure Advocacy Alliance, have ... self awareness and the need for,increased access to ... (Logo: http://www.newscom.com/cgi-bin/prnh/20070122/NYM084LOGO ), Komen for the ...
... Companies Will Discuss Recent FDA Advisory Regarding Byetta, ... LLY ) and Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN ... 2008 at 5:00 p.m. EDT to discuss the,recent FDA ... Lilly will be Donald Therasse, M.D., vice president of ...
... fail to alert docs to effectiveness of alternative therapies ... slowed the use of antipsychotic drugs in seniors with ... the elderly increased, a finding which suggests that warnings ... say. , Between late 2002 and June 2005, ...
... HCA marked its 40th,anniversary during a special program for ... featured HCA Co-Founder and Chairman Emeritus, Dr. Thomas,Frist, Jr. ... who spoke about,HCA,s founding, mission and tradition of caring ... of Caring" program was a,prelude to HCA,s annual Caring ...
Cached Medicine News:Health News:Shaping Best Practices For Standardized Medical Imaging In Clinical Trials 2Health News:Shaping Best Practices For Standardized Medical Imaging In Clinical Trials 3Health News:NitiBrite™ - Break-through in Nitinol Wire Product for Medical Devices 2Health News:Komen Travels to Democratic Convention in Denver to Raise Awareness of Breast Cancer Issues 2Health News:Lilly and Amylin Set Date and Time for Conference Call 2Health News:Antipsychotic Drug Use Up in Elderly Despite Warnings 2Health News:HCA Celebrates 40th Anniversary 2
... To Manually Dilate A Small Pupil With ... Maximizes Safety By Allowing The Iris Hooks ... To The Plane Of The Anterior Capsule, ... Tears. Pupil Stretching Is Also Maximized, With ...
... To Rest Either Nasally Or Temporally ... Allowing Eyelids To Be Opened From ... Possible Aperture., ,Open And Close With ... To The Globe During Clear Corneal ...
... Designed To Rest Either Nasally Or ... Over, Allowing Eyelids To Be Opened ... Widest Possible Aperture.,Open And Close With ... To The Globe During Clear Corneal ...
... Special Low-profile Hourglass Jaw Design Holds ... A Minimal Incision.,Mirror Polished Blades Keep ... Handle Mechanism Offers Control Over Release ... The Lens From Tilting During Insertion.,Reusable, ...
Medicine Products: